Tags

Type your tag names separated by a space and hit enter

Oestrogen receptor 1 mRNA is a prognostic factor in ovarian cancer patients treated with neo-adjuvant chemotherapy: determination by array and kinetic PCR in fresh tissue biopsies.
Endocr Relat Cancer. 2009 Dec; 16(4):1241-9.ER

Abstract

Oestrogen receptors (ESRs) regulate the growth and differentiation of normal ovarian epithelia. However, to date their role as biomarkers in the clinical setting of ovarian cancer remains unclear. In view of potential endocrine treatment options, we tested the role of ESR1 mRNA expression in ovarian cancer in the context of a neo-adjuvant chemotherapy trial. Study participants had epithelial ovarian or peritoneal carcinoma unsuitable for optimal upfront surgery and were treated with neo-adjuvant platinum-based chemotherapy before surgery. RNA was isolated from frozen tumour biopsies before treatment. RNA expression of ESR1 was determined by microarray and reverse transcriptase kinetic PCR technologies. The prognostic value of ESR1 was tested using univariate and multivariate Cox proportional hazards models, Kaplan-Meier survival statistics and the log-rank test. ESR1 positively correlates with proliferation markers and histopathological grading. ESR1 was a significant predictor of survival as a continuous variable in the univariate Cox regression analysis. In multivariate analysis, elevated baseline ESR1 mRNA levels predicted prolonged progression-free survival (P=0.041) and overall survival (P=0.01) after neo-adjuvant chemotherapy, independently of pathological grade and age. We conclude that pretreatment ESR1 mRNA is associated with tumour growth and is a strong prognostic factor in ovarian cancer, independent of the strongest clinical parameters used in clinical routine. We suggest that ESR1 mRNA status should be considered in order to minimize possible confounding effects in ovarian cancer clinical trials, and that early treatment with anti-hormonal agents based on reliable hormone receptor status determination is worth investigating.

Authors+Show Affiliations

Medical Oncology Unit, Policlinico S.Orsola-Malpighi Hospital, Bologna, Italy. claudio.zamagni@aosp.bo.itNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

19749010

Citation

Zamagni, Claudio, et al. "Oestrogen Receptor 1 mRNA Is a Prognostic Factor in Ovarian Cancer Patients Treated With Neo-adjuvant Chemotherapy: Determination By Array and Kinetic PCR in Fresh Tissue Biopsies." Endocrine-related Cancer, vol. 16, no. 4, 2009, pp. 1241-9.
Zamagni C, Wirtz RM, De Iaco P, et al. Oestrogen receptor 1 mRNA is a prognostic factor in ovarian cancer patients treated with neo-adjuvant chemotherapy: determination by array and kinetic PCR in fresh tissue biopsies. Endocr Relat Cancer. 2009;16(4):1241-9.
Zamagni, C., Wirtz, R. M., De Iaco, P., Rosati, M., Veltrup, E., Rosati, F., Capizzi, E., Cacciari, N., Alboni, C., Bernardi, A., Massari, F., Quercia, S., D'Errico Grigioni, A., Dietel, M., Sehouli, J., Denkert, C., & Martoni, A. A. (2009). Oestrogen receptor 1 mRNA is a prognostic factor in ovarian cancer patients treated with neo-adjuvant chemotherapy: determination by array and kinetic PCR in fresh tissue biopsies. Endocrine-related Cancer, 16(4), 1241-9. https://doi.org/10.1677/ERC-08-0342
Zamagni C, et al. Oestrogen Receptor 1 mRNA Is a Prognostic Factor in Ovarian Cancer Patients Treated With Neo-adjuvant Chemotherapy: Determination By Array and Kinetic PCR in Fresh Tissue Biopsies. Endocr Relat Cancer. 2009;16(4):1241-9. PubMed PMID: 19749010.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Oestrogen receptor 1 mRNA is a prognostic factor in ovarian cancer patients treated with neo-adjuvant chemotherapy: determination by array and kinetic PCR in fresh tissue biopsies. AU - Zamagni,Claudio, AU - Wirtz,Ralph M, AU - De Iaco,Pierandrea, AU - Rosati,Marta, AU - Veltrup,Elke, AU - Rosati,Federica, AU - Capizzi,Elisa, AU - Cacciari,Nicoletta, AU - Alboni,Carlo, AU - Bernardi,Alessandra, AU - Massari,Francesco, AU - Quercia,Sara, AU - D'Errico Grigioni,Antonietta, AU - Dietel,Manfred, AU - Sehouli,Jalid, AU - Denkert,Carsten, AU - Martoni,Andrea Angelo, Y1 - 2009/09/11/ PY - 2009/9/15/entrez PY - 2009/9/15/pubmed PY - 2010/2/17/medline SP - 1241 EP - 9 JF - Endocrine-related cancer JO - Endocr Relat Cancer VL - 16 IS - 4 N2 - Oestrogen receptors (ESRs) regulate the growth and differentiation of normal ovarian epithelia. However, to date their role as biomarkers in the clinical setting of ovarian cancer remains unclear. In view of potential endocrine treatment options, we tested the role of ESR1 mRNA expression in ovarian cancer in the context of a neo-adjuvant chemotherapy trial. Study participants had epithelial ovarian or peritoneal carcinoma unsuitable for optimal upfront surgery and were treated with neo-adjuvant platinum-based chemotherapy before surgery. RNA was isolated from frozen tumour biopsies before treatment. RNA expression of ESR1 was determined by microarray and reverse transcriptase kinetic PCR technologies. The prognostic value of ESR1 was tested using univariate and multivariate Cox proportional hazards models, Kaplan-Meier survival statistics and the log-rank test. ESR1 positively correlates with proliferation markers and histopathological grading. ESR1 was a significant predictor of survival as a continuous variable in the univariate Cox regression analysis. In multivariate analysis, elevated baseline ESR1 mRNA levels predicted prolonged progression-free survival (P=0.041) and overall survival (P=0.01) after neo-adjuvant chemotherapy, independently of pathological grade and age. We conclude that pretreatment ESR1 mRNA is associated with tumour growth and is a strong prognostic factor in ovarian cancer, independent of the strongest clinical parameters used in clinical routine. We suggest that ESR1 mRNA status should be considered in order to minimize possible confounding effects in ovarian cancer clinical trials, and that early treatment with anti-hormonal agents based on reliable hormone receptor status determination is worth investigating. SN - 1479-6821 UR - https://www.unboundmedicine.com/medline/citation/19749010/Oestrogen_receptor_1_mRNA_is_a_prognostic_factor_in_ovarian_cancer_patients_treated_with_neo_adjuvant_chemotherapy:_determination_by_array_and_kinetic_PCR_in_fresh_tissue_biopsies_ L2 - https://erc.bioscientifica.com/doi/10.1677/ERC-08-0342 DB - PRIME DP - Unbound Medicine ER -